

- **Name:** Ji-Youn Han
  - **Current Position & Affiliation:** Principal Scientist, National Cancer Center, Center for Lung Cancer
  - **Country:** Republic of Korea
- 

• **Educational Background:**

Graduated in 1989 from the College of Medicine, the Catholic University of Korea, Seoul, Korea, and obtained her MS and PhD degrees in internal medicine in 1995 and 1998, respectively.

• **Professional Experience:**

I joined National Cancer Center since 2001 and directed the Center for Lung Cancer from 2010 to 2017 and the Division of Precision Medicine from 2016 to Mar. 2019. In 2003-2004, she joined the University of Texas MD Anderson Cancer Center in Texas, USA as a visiting assistant professor. In 2016-2017, she was an elected member of the Presidential Advisory Council on Science & Technology and contributed the National Precision Medicine Project.

• **Professional Organizations:**

N/A

• **Main Scientific Publications:**

1. Soo RA and JY Han et al. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial. *Ann Oncol* 2022;33:181-192
2. Shin DH et al. Oncogenic KRAS promotes growth of lung cancer cells expressing SLC3A2-NRG1 fusion via ADAM17-mediated shedding of NRG1. *Oncogene* 2022;41:280-292
3. Cho BC et al. A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors. *J Thorac Oncol* 2022;17:558-567
4. Dafni U et al. Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis. *ESMO Open* 2022;7:100507
5. Lim MY et al. Diagnostic and prognostic potential of the oral and gut microbiome for lung adenocarcinoma. *Clin Transl Med* 2021 (Epub)
6. Lee Y et al. One-Step Polymerase Chain Reaction-Free Nanowire-Based Plasma Cell-Free DNA Assay to Detect EML4-ALK Fusion and to Monitor Resistance in Lung Cancer. *Oncologist* 2021 (Epub)
7. Choi WY et al. The Clinical Impact of Capmatinib in the Treatment of Advanced Non-Small Cell

Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification. *Cancer Treat Res* 2021;53:1024-1032

8. Dziadziuszko R et al. Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort. *J Thorac Oncol* 2021 (Epub)
9. Park K et al. Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. *J Clin Oncol* 2021;39:3391-3402
10. Camidge DR et al. Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial. *J Thorac Oncol* 2021 (Epub)
11. Byers LA et al. A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer. *Clin Lung Cancer* 2021;22:531-540
12. Jang SB et al. Cardiac Safety Assessment of Lazertinib: Findings From Patients With EGFR Mutation-Positive Advanced NSCLC and Preclinical Studies. *JTO Clin Res Reports*. 2021;2:100224
13. Drlon A et al. Clinicopathologic Features and Response to Therapy of NRG1 Fusion–Driven Lung Cancers: The eNRGy1 Global Multicenter Registry. *J Clin Oncol* 2021;39:2791-2802
14. Herbst R et al. Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC. *J Thorac Oncol* 2021;16:1718-1732
15. Park K et al. Olmutinib in T790M-Positive Non–Small Cell Lung Cancer After Failure of First-Line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy: A Global, Phase 2 Study. *Cancer* 2021;127:1407-16
16. Paik PK, Felip E, Veillon R, Sakai H, et al. Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. *N Engl J Med* 2020;383:931-943
17. Wolf J, Seto T, Han JY, et al. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. *N Engl J Med* 2020;383:944-957
18. Schuler M, et al. Molecular Correlates of Response to Capmatinib in Advanced Non-Small-Cell Lung Cancer: Clinical and Biomarker Results From a Phase I Trial. *Ann Oncol*. 2020 Mar 30:S0923-7534(20)36380-8
19. Herbst RS, et al. Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1–Positive, Advanced Non–Small-Cell Lung Cancer in the KEYNOTE-010 Study. *J Clin Oncol*. 2020 May 10;38(14):1580-1590
20. Sequist LV, Han JY (co-first), et al. Osimertinib Plus Savolitinib in Patients With EGFR Mutation-Positive, MET-amplified, Non-Small-Cell Lung Cancer After Progression on EGFR Tyrosine Kinase Inhibitors: Interim Results From a Multicentre, Open-Label, Phase 1b Study. *Lancet Oncol*. 2020 Mar;21(3):373-386.